For in depth information about the KRAS-variant and a community of others who have been tested and are involved in the research around the KRAS-variant, please visit, and encourage your patient to visit, our non-profit sister company, MiraKind.

My patient tested positive for the KRAS-variant but has never had cancer:

  • This information could indicate that your patient is at an increased risk of breast, ovarian or lung cancer – about 2-6 times greater than the average person. Studies have shown that abrupt estrogen withdrawal is a trigger for cancer for women with the KRAS-variant.
  • Other physicians have reported to do the following for their KRAS-variant positive/cancer free patients:
    • Because KRAS-variant women are at higher breast cancer risk (Paranjape), get higher level breast cancer screening. As the KRAS-variant predicts over a 20% lifetime risk of breast cancer per ACS guidelines patients should be eligible for higher level breast cancer screening.
    • Because KRAS-variant women are at higher ovarian cancer risk (Ratner), for patients who are peri-menopausal or postmenopausal continue appropriate gynecological screening of the ovaries, and when post-menopausal, consider outpatient surgery to remove the fallopian tubes and ovaries if felt to be most appropriate.
    • Due to increased ovarian cancer risk (Ratner), consider oophorectomy at the time of hysterectomy for non-cancerous reasons, but due to increased cancer risk with abrupt estrogen withdrawal (McVeigh), plan for estrogen continuation throughout.
    • Due to an increased lung cancer risk, strongly advocate for smoking cessation (Chin).
    • Consider HRT for women who are peri-menopausal, and avoid abrupt estrogen withdrawal (McVeigh).
    • Avoid anti-estrogen therapies for cancer prevention in these patients, such as Tamoxifen (McVeigh).
    • Our sister non-profit is conducting studies to define the best estrogen management strategies for women with the KRAS-variant, to minimize cancer risk.  Consider having your patients join one of these studies at MiraKind.

My patient has tested positive for the KRAS-variant and has been diagnosed with cancer:

  • This finding suggests that your patients cancer diagnosis could be due to this genetic factor, and they may be at an elevated risk of developing a second, independent cancer.
  • Based on an extensive body of literature, your patient is likely to have a unique response to cancer therapy.
  • Other physicians have reported to do the following for their KRAS-variant positive/cancer patients:
    • Because KRAS-variant breast cancer patients are at an elevated risk of developing an independent second breast cancer (McVeigh), high level screening is indicated.
    • Because KRAS-variant breast cancer patients are at an elevated risk of ovarian cancer (Pilarski), high level screening or oophorectomy should be considered.
    • Because KRAS-variant patients have been shown to be resistant to platinum agents (Ratner)(Chung), consideration of other agents or clinical trials should be considered.
    • Because KRAS-variant patients with HNSCC have been found to do poorly (Chung), even when HPV positive, to radiation plus cisplatin therapy (Chung), consideration should be made for the addition of cetuximab, or a clinical trial.
    • Because KRAS-variant patients appear to have a weak immune system (Chung), testing of our other developing biomarkers should be considered when enrolling them in immune therapy trials.